Cargando…
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096968/ https://www.ncbi.nlm.nih.gov/pubmed/20920193 http://dx.doi.org/10.1186/bcr2719 |
_version_ | 1782203772665069568 |
---|---|
author | Pinhel, Isabel F MacNeill, Fiona A Hills, Margaret J Salter, Janine Detre, Simone A'Hern, Roger Nerurkar, Ashutosh Osin, Peter Smith, Ian E Dowsett, Mitch |
author_facet | Pinhel, Isabel F MacNeill, Fiona A Hills, Margaret J Salter, Janine Detre, Simone A'Hern, Roger Nerurkar, Ashutosh Osin, Peter Smith, Ian E Dowsett, Mitch |
author_sort | Pinhel, Isabel F |
collection | PubMed |
description | INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at surgery and (2) between core-cuts and resected tumours. METHODS: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were investigated. RESULTS: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively; both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy specimens for p-Erk1/2 (P = 0.01). CONCLUSIONS: The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers. |
format | Text |
id | pubmed-3096968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30969682011-05-18 Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer Pinhel, Isabel F MacNeill, Fiona A Hills, Margaret J Salter, Janine Detre, Simone A'Hern, Roger Nerurkar, Ashutosh Osin, Peter Smith, Ian E Dowsett, Mitch Breast Cancer Res Research Article INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at surgery and (2) between core-cuts and resected tumours. METHODS: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were investigated. RESULTS: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively; both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy specimens for p-Erk1/2 (P = 0.01). CONCLUSIONS: The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers. BioMed Central 2010 2010-09-28 /pmc/articles/PMC3096968/ /pubmed/20920193 http://dx.doi.org/10.1186/bcr2719 Text en Copyright ©2010 Pinhel et al.; licensee BioMed Central Ltd http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Pinhel, Isabel F MacNeill, Fiona A Hills, Margaret J Salter, Janine Detre, Simone A'Hern, Roger Nerurkar, Ashutosh Osin, Peter Smith, Ian E Dowsett, Mitch Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title_full | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title_fullStr | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title_full_unstemmed | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title_short | Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer |
title_sort | extreme loss of immunoreactive p-akt and p-erk1/2 during routine fixation of primary breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096968/ https://www.ncbi.nlm.nih.gov/pubmed/20920193 http://dx.doi.org/10.1186/bcr2719 |
work_keys_str_mv | AT pinhelisabelf extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT macneillfionaa extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT hillsmargaretj extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT salterjanine extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT detresimone extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT ahernroger extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT nerurkarashutosh extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT osinpeter extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT smithiane extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer AT dowsettmitch extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer |